Skip to main content
Erschienen in: Pituitary 4/2012

01.12.2012

Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas

verfasst von: Erica Hightower, Maria E. Cabanillas, Greg N. Fuller, Ian E. McCutcheon, Kenneth R. Hess, Komal Shah, Steven G. Waguespack, Lynda J. Corley, Jessica K. Devin

Erschienen in: Pituitary | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Nonfunctioning pituitary adenomas (NFPA) are typically benign neoplasms that can cause significant morbidity through local mass effects. MIB-1/Ki-67 and p53 immuno-reactivity are used to predict aggressive behavior but have known limitations. No marker to date is widely used to reliably predict tumor progression. Phospho-histone H3 (pHH3) is a protein phosphorylated during chromatin condensation in mitosis, and thus anti-pHH3 immunocytochemistry is able to assess mitotic activity. Study objectives were to determine the relationship among pHH3, MIB-1/Ki-67, and p53 in NFPA, and to evaluate the relationship between these indices and time to progression (TTP). Seventy-six patients with NFPA operated on by a single neurosurgeon at University of Texas M. D. Anderson Cancer Center from 1992 to 2006 were identified from a database and met all criteria for inclusion in this clinicopathology study. PHH3, MIB-1/Ki-67, and p53 immuno-reactivity was evaluated in each case. Retrospective review was used to determine TTP. With 282 person-years of follow-up, 19 progression events were observed. A correlation was found between MIB-1/Ki-67 and p53 immuno-reactivity (r = 0.25, p = 0.031). PHH3 did not correlate with either. When markers were dichotomized at the median, only MIB-1/Ki-67 correlated with TPP (log rank p = 0.018). Rank correlation analysis confirmed a significant inverse correlation between both MIB-1/Ki-67 (Dxy = −0.33, p = 0.036) and p53 (Dxy = −0.40, 0.016) immuno-reactivity and TTP. Our results support previous data suggesting that MIB-1/Ki-67 and p53 have clinical utility as prognostic markers for tumor progression. PHH3 did not prove to be associated with TTP in this retrospective study limited by few progression events.
Literatur
2.
Zurück zum Zitat Schreiber S, Saeger W, Ludecke DK (1999) Proliferation markers in different types of clinically non-secreting pituitary adenomas. Pituitary 1:213–220PubMedCrossRef Schreiber S, Saeger W, Ludecke DK (1999) Proliferation markers in different types of clinically non-secreting pituitary adenomas. Pituitary 1:213–220PubMedCrossRef
3.
Zurück zum Zitat Gurlek A, Karavitaki N, Ansorge O, Wass JAH (2007) What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 156:143–153PubMedCrossRef Gurlek A, Karavitaki N, Ansorge O, Wass JAH (2007) What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 156:143–153PubMedCrossRef
4.
Zurück zum Zitat Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Monting J, Reincke M (2003) Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg 99:674–679PubMedCrossRef Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Monting J, Reincke M (2003) Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg 99:674–679PubMedCrossRef
5.
Zurück zum Zitat Kontogeorgos G (2006) Predictive markers of pituitary adenoma behavior. Neuroendocrinology 83:179–188PubMedCrossRef Kontogeorgos G (2006) Predictive markers of pituitary adenoma behavior. Neuroendocrinology 83:179–188PubMedCrossRef
6.
7.
Zurück zum Zitat Hentschel SJ, McCutcheon IE, Moore W, Durity FA (2003) p53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci 30:215–219PubMed Hentschel SJ, McCutcheon IE, Moore W, Durity FA (2003) p53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci 30:215–219PubMed
8.
Zurück zum Zitat Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R, Veglia F, Mortini P, Giovanelli M (2000) Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery 47:1313–1319PubMedCrossRef Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R, Veglia F, Mortini P, Giovanelli M (2000) Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery 47:1313–1319PubMedCrossRef
9.
Zurück zum Zitat Suzuki M, Minematsu T, Oyama K, Tahara S, Miyai S, Sanno N, Osamura RY, Teramoto A (2006) Expression of proliferation markers in human pituitary incidentalomas. Endocr Pathol 17:263–276PubMedCrossRef Suzuki M, Minematsu T, Oyama K, Tahara S, Miyai S, Sanno N, Osamura RY, Teramoto A (2006) Expression of proliferation markers in human pituitary incidentalomas. Endocr Pathol 17:263–276PubMedCrossRef
10.
Zurück zum Zitat Colman H, Giannini C, Huang L, Gonzalez J, Hess K, Bruner J, Fuller G, Langford L, Pelloski C, Aaron J, Burger P, Aldape K (2006) Assessment and prognostic significance of mitotic index using the mitosis marker phoso-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol 30:657–664PubMedCrossRef Colman H, Giannini C, Huang L, Gonzalez J, Hess K, Bruner J, Fuller G, Langford L, Pelloski C, Aaron J, Burger P, Aldape K (2006) Assessment and prognostic significance of mitotic index using the mitosis marker phoso-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol 30:657–664PubMedCrossRef
11.
Zurück zum Zitat Ribalta T, McCutcheon IE, Aldape KD, Bruner JM, Fuller GN (2004) The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol 28:1532–1536PubMedCrossRef Ribalta T, McCutcheon IE, Aldape KD, Bruner JM, Fuller GN (2004) The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol 28:1532–1536PubMedCrossRef
12.
Zurück zum Zitat Prevedello DM, Jagannathan J, John JA Jr, Lopes BS, Laws ER Jr (2005) Relevance of high Ki-67 in pituitary adenomas. Neurosurg Focus 19:E11PubMedCrossRef Prevedello DM, Jagannathan J, John JA Jr, Lopes BS, Laws ER Jr (2005) Relevance of high Ki-67 in pituitary adenomas. Neurosurg Focus 19:E11PubMedCrossRef
13.
Zurück zum Zitat Turner HE, Wass JAH (1999) Are markers of proliferation valuable in the histological assessment of pituitary tumors? Pituitary 1:147–151PubMedCrossRef Turner HE, Wass JAH (1999) Are markers of proliferation valuable in the histological assessment of pituitary tumors? Pituitary 1:147–151PubMedCrossRef
14.
Zurück zum Zitat Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposita V, Bultrini A, Ferretti E, Santoro A, Faticanti Scucchi L, Gulino A, Cantore G (2002) A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tymours: secreting versus non-secreting adenomas. Endocr Relat Cancer 9:103–113PubMedCrossRef Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposita V, Bultrini A, Ferretti E, Santoro A, Faticanti Scucchi L, Gulino A, Cantore G (2002) A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tymours: secreting versus non-secreting adenomas. Endocr Relat Cancer 9:103–113PubMedCrossRef
15.
Zurück zum Zitat Scheithauer BW, Gaffey TA, Lloyd V, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF Jr, Meyer FB, Kuroki T, Riehle DL, Laws ER Jr (2006) Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59:341–353PubMedCrossRef Scheithauer BW, Gaffey TA, Lloyd V, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF Jr, Meyer FB, Kuroki T, Riehle DL, Laws ER Jr (2006) Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59:341–353PubMedCrossRef
16.
Zurück zum Zitat Wolfsberger S, Wunderer J, Zachenhofer I, Czech T, Bocher-Schwarz HG, Hainfellner J, Knosp E (2004) Expression of cell proliferation markers in pituitary adenomas-correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha. Acta Neurochir 146:831–839 Wolfsberger S, Wunderer J, Zachenhofer I, Czech T, Bocher-Schwarz HG, Hainfellner J, Knosp E (2004) Expression of cell proliferation markers in pituitary adenomas-correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha. Acta Neurochir 146:831–839
17.
Zurück zum Zitat Paek KI, Kim SH, Song SH, Choi SW, Koh HS, Youm JY, Kim Y (2005) Clinical significance of Ki-67 labeling index in pituitary macroadenomas. J Korean Med Sci 20:489–494PubMedCrossRef Paek KI, Kim SH, Song SH, Choi SW, Koh HS, Youm JY, Kim Y (2005) Clinical significance of Ki-67 labeling index in pituitary macroadenomas. J Korean Med Sci 20:489–494PubMedCrossRef
18.
Zurück zum Zitat Fillipella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G, Colao A, Meduri G, Chanson P (2006) Pituitary tumor transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol 65:536–543CrossRef Fillipella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G, Colao A, Meduri G, Chanson P (2006) Pituitary tumor transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol 65:536–543CrossRef
19.
Zurück zum Zitat Takei H, Battacharjee MB, Rivera A, Dancer Y, Powerll SZ (2007) New immunohistochemical markers in the evaluation of central nervous system tumors. Arch Pathol Lab Med 131:234–241PubMed Takei H, Battacharjee MB, Rivera A, Dancer Y, Powerll SZ (2007) New immunohistochemical markers in the evaluation of central nervous system tumors. Arch Pathol Lab Med 131:234–241PubMed
20.
Zurück zum Zitat Grundy M, Seedhouse C, Shang S, Richardson J, Russell N, Pallis M (2010) The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells. Mol Cancer Ther 9:661–672PubMedCrossRef Grundy M, Seedhouse C, Shang S, Richardson J, Russell N, Pallis M (2010) The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells. Mol Cancer Ther 9:661–672PubMedCrossRef
Metadaten
Titel
Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas
verfasst von
Erica Hightower
Maria E. Cabanillas
Greg N. Fuller
Ian E. McCutcheon
Kenneth R. Hess
Komal Shah
Steven G. Waguespack
Lynda J. Corley
Jessica K. Devin
Publikationsdatum
01.12.2012
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 4/2012
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-011-0367-3

Weitere Artikel der Ausgabe 4/2012

Pituitary 4/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.